Senate Confirms Dr. Satcher as Surgeon General

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--David Satcher, MD, PhD, won confirmation as US Surgeon General by a 63 to 35 vote after 75 members of the Senate voted to end a filibuster led by Sen. John D. Ashcroft (R-Mo).

WASHINGTON--David Satcher, MD, PhD, won confirmation as US Surgeon General by a 63 to 35 vote after 75 members of the Senate voted to end a filibuster led by Sen. John D. Ashcroft (R-Mo).

Dr. Satcher, who had served as director of the Centers for Disease Control and Prevention (CDC) since November 1993, will fill the key health post, which has been vacant since Joycelyn Elders, MD, resigned under pressure 3 years ago.

President Clinton hailed the bipartisan vote for Dr. Satcher, whom he described as "a mainstream physician who is an eloquent advocate for the health of all Americans." Dr. Satcher will also serve as assistant secretary for health, Department of Health and Human Services.

Strong support existed for Dr. Satcher’s nomination in the Senate and from many medical, health profession, and advocacy groups. However, his confirmation had been fought since his nomination last September by a group of senators who objected to Dr. Satcher’s opposition to legislation that would outright ban so-called partial-birth abortions without regard to the mother’s health and for his support of needle-exchange programs instituted to prevent the spread of AIDS.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content